Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 10/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.46 |
| ▸ | FPR1 | P21462 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1749157 | 0.93 | HRH3 (0.53) | MCHR1S1PR2KDM4ELMNASMN1; SMN2 | |
| SCHEMBL12529014 | 0.87 | MCHR1 (0.65) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL12529112 | 0.86 | MCHR1 (0.51) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL12528881 | 0.83 | MCHR1 (0.75) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL12528767 | 0.83 | MCHR1 (0.64) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL12529050 | 0.82 | MCHR1 (0.59) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL12529120 | 0.81 | MCHR1 (0.59) | MCHR1 | |
| SCHEMBL12529071 | 0.81 | MCHR1 (0.57) | MCHR1KDM4ELMNASMN1; SMN2CA12 | |
| SCHEMBL5912424 | 0.81 | S1PR2 (0.65) | S1PR2LMNASMN1; SMN2CA12CA2 | |
| SCHEMBL12529144 | 0.80 | MCHR1 (0.71) | MCHR1LMNASMN1; SMN2MAPTFPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223788-B2 | therapy for eating disorders, anorexigenic agents, antidiabetic agents, reducing weight in mammals, circadian rhythm disease, psychological disorders | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | MCHR1 2068/4885S1PR2 3277/4885KDM4E 2896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.